Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

Publication | Open Access

DOI Full Paper Access

Citations

References

2014

Year

Lishomwa C. Ndhlovu, Tracie M Umaki, Glen M. Chew, Dominic C. Chow, Melissa Agsalda, Kalpana J. Kallianpur, Robert Paul, Guangxiang Zhang, Erika Ho, Nancy Hanks,

Journal of NeuroVirology

NeuropsychologyCd16-expressing MonocytesCognitive PerformanceTreatment And PreventionNeurovirologyTreatment IntensificationMedicineHuman RetrovirusAntiviral ResponseCcr5 AntagonistNeurologyNeuroscienceChronic Viral InfectionHivNeuroimmunologySocial Sciences